The annual J.P. Morgan Healthcare Conference convenes thousands of healthcare investors, global industry leaders and technology innovators to explore the key trends shaping the industry in 2026 and beyond. If you would ...

Demographic Matching in Organ Impairment Studies: Why It Matters Organ impairment (OI) studies are critical for safe and effective drug development—but did you know that demographic matching can make or break the accurac...

Integrating modern technologies and careful preparation can contribute significantly to supporting and enhancing the performance of the people who make cardiovascular outcome trials function. Read the article for human-c...

Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...

For medical device developers selecting the right AI model and data is crucial to capitalise on this powerful technology. Our new whitepaper explains best practices for AI-enabled devices. Learn about AI models, datase...

Do you know the difference between decision trees and random forests? Learn about AI models for SaMDs in our new whitepaper. Download it now to learn best practices for model and data selection. https://ow.ly/nI8g50XAzbq

Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.

The future of clinical development is digital. From wearable sensors to AI-powered analysis, sponsors who embrace digital strategies will gain faster decisions, better data, and stronger regulatory confidence. Get a ste...

Site-centricity is no longer optional. ICON’s whitepaper reveals how early engagement and dedicated support drive faster, more predictable trials. Download here: https://ow.ly/vSms50XB73q

CRAs are no longer just monitors, they’re strategic site partners. Discover how tech is driving this shift in this ACT article featuring ICON’s Helen Yeardley. https://ow.ly/3qob50XB6Vo

Driving compliance in fully remote Alzheimer’s trials is complex, ICON Concierge Services makes it possible. In a pre-clinical study with 600+ participants and over 50 ePROs per patient, Concierge direct-to-patient serv...

Successful execution of a cardiovascular outcome trial depends on patient retention — but there are other areas of a CVOT where considering the human element is crucial as well. Explore how people impact multiple dimensi...